Introduction
Carboxylases, enzymes that catalyze the addition of a CO2 molecule to an organic substrate, are as diverse as their mechanisms are. They play a variety of physiological roles. Multiple Carboxylase Deficiency (MCD) is an inherited metabolic disorder categorized as an organic acid disorder. It arises from insufficient enzymes necessary for converting protein into energy. This article discusses more of this disorder.
What Is Multiple Carboxylase Deficiency?
Multiple Carboxylase Deficiency (MCD) is called Holocarboxylase synthetase (HCS) deficiency. HLCS gene mutations cause holocarboxylase synthetase deficiency. Making the Holocarboxylase synthetase enzyme is controlled by the HLCS gene. The efficient utilization of biotin, a B vitamin in foods including milk, liver, and egg yolks, depends on this enzyme. It is a group of disorders defined by the reduced function of specific biotin-dependent enzymes. Certain enzymes are necessary for the body's regular synthesis and digestion of proteins, lipids, and carbohydrates and are linked with biotin by Holocarboxylase synthetase. Mutations in the HLCS gene decrease the enzyme's capacity to bind biotin to these enzymes, impeding correct nutrition processing and interfering with other cellular processes.
Moreover, The enzymes that covalently connect biotin to three carboxylases—propionyl-CoA carboxylase, pyruvate carboxylase, and 3-methylcrotonyl-CoA carboxylase—Holocarboxylase synthetase deficiency is a deficiency, thereby leading to inability to use the vitamin biotin effectively. While the precise prevalence of this condition remains uncertain, it is estimated that approximately 1 in 87,000 individuals may be affected. Both copies of the gene in each parent should have mutations for this genetic disorder to occur, as it is autosomally recessive. However, usually, neither parent exhibits the disease's signs and symptoms.
What Are the Other Names of Multiple Carboxylase Deficiency?
-
Infantile multiple carboxylase deficiency.
-
Biotidinase deficiency.
-
Biotin-(propionyl-CoA-carboxylase) ligase deficiency.
-
Biotin-(propionyl-coenzyme A-carboxylase) ligase deficiency.
-
Early-onset biotin-responsive multiple carboxylase deficiency.
-
Early-onset combined carboxylase deficiency.
What Are the Symptoms of Multiple Carboxylase Deficiency?
The characteristic signs and symptoms of holocarboxylase synthetase deficiency typically manifest within the initial months after birth, although the age of onset can vary. Infants with the condition frequently struggle to eat and experience breathing difficulties, skin rash, vomiting, seizures, baldness, strong-odored urine, and lethargy. The disease can cause unconsciousness, intellectual disability, coma, metabolic keto lactic acidosis, seizures, optic atrophy, recurrent infections, and delayed growth if ignored. In some situations, it could be fatal. In a case report, metabolic ketoacidosis, hyperammonemia, organic aciduria, seizures, and coma were observed in a newborn baby. Patients who are not treated have moderate to severe mental impairments or retardation. Hearing loss can also occur.
How Is Multiple Carboxylase Deficiency Diagnosed?
-
Newborn Screening: Infants may be referred to a feeding clinic and a gastrointestinal specialist. Due to the ease with which the metabolic problem is treated, and symptoms are cured in these patients, the doctor should confirm the "normal" newborn screen. Within days of delivery, newborn screening using dried blood spots can identify biotinidase deficiency. Common mutations are found during newborn screening, and the biotinidase assay is used to establish the absence of the condition.Even with the same mutation, biotinidase activity varies from person to person, suggesting that there may be epigenetic variables controlling the amount of the enzyme. While partial biotinidase insufficiency seems prevalent and may be associated with moderate clinical signs or none at all, severe biotinidase deficiency is uncommon. There are numerous late-onset types. The majority of late-onset forms went unidentified before the implementation of newborn screening. In the third and fourth decades of life, slight learning difficulties, hearing loss, and mild skin abnormalities have been observed together with mild-to-moderate enzyme deficits with enzyme levels in the 20% to 30% regular mean enzyme activity. It is crucial to inform the family that each child has a 25% chance of inheriting a genetic mutation and developing biotinidase deficiency. The other children should be tested if the newborn screening results cannot be verified.
-
Urine Analysis: Plasma carnitine, plasma acylcarnitine profile, plasma amino acids, and urine organic acids are diagnostic procedures performed on a typical urine sample.
-
Gene Analysis: HLCS gene analysis- Now, utilizing tandem mass spectrometry and enhanced newborn screening, this metabolic anomaly should be found in all affected newborns and result in presymptomatic therapy. Once an enzyme deficit is identified, a genetics center is contacted to confirm the diagnosis and begin therapy for the kid and family.
How Is Multiple Carboxylase Deficiency Treated?
-
Biotin Supplementation:
Many of these disorders caused by multiple carboxylase deficiency may be avoided with prompt treatment and supportive care using biotin supplements. A case report reported that after introducing oral biotin at pharmacologic levels for a few days, the infant's neurologic and metabolic health significantly improved. About 5 to 10 mg of biotin is given orally daily to newborns. As the child ages, the daily oral dose of biotin may be increased to 15 to 20 mg (milligrama). Both liquid solutions and tablets of biotin are available. One can add biotin in trace amounts to cereal or other foods. Adults may receive up to 100mg of medication daily. There isn't any evidence to support the doses now advised, although biotin isn't hazardous. The clinical course of treatment does not appear to be affected by routinely measuring biotinidase activity. The levels of biotinidase change over time and are influenced by laboratory techniques.
A severe deficiency of 5% or less is likely to have clinical repercussions if treated right away. For levels under 30 % of the mean average level, therapy is regarded as necessary.
Treatment is for a life-long duration. Levels between 15% and 30% of the mean average level are regarded as intermediate or moderate deficiencies. They are not likely to be linked to metabolic decompensation during stressful situations like illnesses or fluid imbalances when using biotin supplements.
Yearly Evaluation: The patient is advised to undergo an annual evaluation by a clinical geneticist to assess their progress and look for any indications of biotinidase deficiency. Every year, hearing and eyesight are evaluated. Maintaining fluid balance and correcting electrolyte imbalances is crucial in the case of acute decompensation. Assays for biotinidase vary from month to month and from year to year.
Conclusion
Multiple carboxylase deficiency treatment is extensively studied and developed like other rare genetic conditions. Early diagnosis and immediate biotin treatment are essential components of the strategy for treating this metabolic condition. Moreover, annual evaluation and the proper intake of biotin supplementation are significant to treat the condition effectively.
